{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:12:19Z","timestamp":1784772739901,"version":"3.55.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"abstract":"<jats:p>Primary Sj\u00f6gren Syndrome (pSS) is a chronic autoimmune disease that primarily affects exocrine glands and can lead to various extraglandular manifestations, including secondary immune thrombocytopenia (ITP). Understanding the clinical and hematological differences in pSS patients with and without secondary ITP is crucial for improved patient management and treatment strategies. This retrospective study, conducted from January 2020 to December 2023, involved a cohort of pSS patients, dividing them into 2 groups: those with secondary ITP and those without. Patients were evaluated using the European League Against Rheumatism Sj\u00f6gren Syndrome Disease Activity Index (ESSDAI), EULAR Sj\u00f6gren Syndrome Patient-Reported Index (ESSPRI), Health Assessment Questionnaire, and other hematological parameters. Inclusion criteria were based on the American-European Consensus Group or ACR\/EULAR classification criteria for pSS. Exclusion criteria included other autoimmune or hematological disorders, prior splenectomy, recent blood transfusions, and lack of informed consent. Statistical analysis was performed using SPSS software, with various tests applied to analyze the data, including logistic regression to identify risk factors for secondary ITP. Significant differences were noted in fatigue, lymphadenopathy, arthritis, mean age, and ESSDAI scores between the secondary ITP and non-secondary ITP groups. Patients with secondary ITP exhibited higher platelet counts, more prevalent lymphopenia, higher immunoglobulin G (IgG) levels, lower complement 3 levels, and reduced white blood cell and hemoglobin levels. Logistic regression analysis identified lymphadenopathy as a risk factor and arthritis as a protective factor for the development of secondary ITP. The study reveals distinct clinical and hematological characteristics in pSS patients with secondary ITP, suggesting a higher disease activity in this subset. These findings underscore the need for further exploration of these associations to develop more precise treatment approaches for pSS, focusing on preventing secondary ITP and improving patient outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000037909","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T14:04:00Z","timestamp":1715349840000},"page":"e37909","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive analysis of the clinical manifestations and hematological parameters associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome: An observational study"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4325-9967","authenticated-orcid":false,"given":"Wenwen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medical Nursing, Cangzhou Medical College, Cangzhou, Hebei Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251125","first-page":"980","article-title":"Sj\u00f6gren\u2019s syndrome.","volume":"20","author":"Andr\u00e9","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"R2-20251125","doi-asserted-by":"crossref","first-page":"e3821","DOI":"10.1136\/bmj.e3821","article-title":"Primary Sjogren syndrome.","volume":"344","author":"Ramos-Casals","year":"2012","journal-title":"BMJ"},{"key":"R3-20251125","doi-asserted-by":"crossref","first-page":"8101503","DOI":"10.1155\/2019\/8101503","article-title":"Sj\u00f6gren\u2019s syndrome: animal models, etiology, pathogenesis, clinical subtypes, and diagnosis.","volume":"2019","author":"Shen","year":"2019","journal-title":"J Immunol Res"},{"key":"R4-20251125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia.","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20251125","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia.","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R6-20251125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fmed.2020.00138","article-title":"Clinical characteristics of secondary immune thrombocytopenia associated with primary Sj\u00f6gren\u2019s Syndrome.","volume":"7","author":"Dai","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R7-20251125","first-page":"2245","article-title":"Factors associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective study of 639 cases.","volume":"40","author":"Luo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R8-20251125","doi-asserted-by":"crossref","first-page":"110716","DOI":"10.1016\/j.intimp.2023.110716","article-title":"Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome.","volume":"123","author":"Sun","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R9-20251125","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide.","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"R10-20251125","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome.","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 39","key":"R11-20251125","first-page":"S14","article-title":"The Health Assessment Questionnaire (HAQ).","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"S11","key":"R12-20251125","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1002\/acr.20579","article-title":"Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for Severity, Effect, and Coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS).","volume":"63","author":"Hewlett","year":"2011","journal-title":"Arthritis Care Res"},{"key":"R13-20251125","first-page":"45","article-title":"Schirmer\u2019s test.","volume":"24","author":"Stevens","year":"2011","journal-title":"Community Eye Health"},{"key":"R14-20251125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.medcli.2022.10.007","article-title":"Sj\u00f6gren syndrome.","volume":"160","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"R15-20251125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4081\/reumatismo.2017.1032","article-title":"The clinical spectrum of primary Sj\u00f6gren\u2019s syndrome: beyond exocrine glands.","volume":"69","author":"Leone","year":"2017","journal-title":"Reumatismo"},{"key":"R16-20251125","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/jcm9072299","article-title":"Current state of knowledge on primary Sj\u00f6gren\u2019s syndrome, an autoimmune exocrinopathy.","volume":"9","author":"Parisis","year":"2020","journal-title":"J Clin Med"},{"key":"R17-20251125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/medicina56120667","article-title":"Immune Thrombocytopenia (ITP): current limitations in patient management.","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"R18-20251125","doi-asserted-by":"crossref","first-page":"368504221102786","DOI":"10.1177\/00368504221102786","article-title":"Eltrombopag improves refractory thrombocytopenia in patients with Sj\u00f6gren\u2019s syndrome.","volume":"105","author":"Xu","year":"2022","journal-title":"Sci Prog"},{"key":"R19-20251125","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3324\/haematol.2021.279513","article-title":"Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment.","volume":"107","author":"Bussel","year":"2022","journal-title":"Haematologica"},{"key":"R20-20251125","first-page":"e49313","article-title":"Idiopathic thrombocytopenic purpura: current limitations and management.","volume":"15","author":"Thakre","year":"2023","journal-title":"Cureus"},{"key":"R21-20251125","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1055\/s-0042-1758546","article-title":"Possible targets to reduce fatigue in chronic immune thrombocytopenia patients \u2013 an explorative study.","volume":"6","author":"van Dijk","year":"2022","journal-title":"TH Open"},{"key":"R22-20251125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.16387","article-title":"Fatigue, executive function and psychological effects in children with immune thrombocytopenia: a cross-sectional study.","volume":"189","author":"Towner","year":"2020","journal-title":"Br J Haematol"},{"key":"R23-20251125","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3389\/fimmu.2019.01827","article-title":"Fatigue, sleep, and autoimmune and related disorders.","volume":"10","author":"Zielinski","year":"2019","journal-title":"Front Immunol"},{"key":"R24-20251125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia.","volume":"170","author":"Hill","year":"2015","journal-title":"Br J Haematol"},{"key":"R25-20251125","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.3390\/jcm12154994","article-title":"Characterizing Sj\u00f6gren-associated fatigue: a distinct phenotype from ME\/CFS.","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"key":"R26-20251125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2019.00470","article-title":"Regulation of immune function by the lymphatic system in lymphedema.","volume":"10","author":"Kataru","year":"2019","journal-title":"Front Immunol"},{"key":"R27-20251125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/17512433.2021.1903315","article-title":"Update on diagnosis and treatment of immune thrombocytopenia.","volume":"14","author":"Sandal","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R28-20251125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0039-1683416","article-title":"Epidemiology and clinical manifestations of immune thrombocytopenia.","volume":"39","author":"Kohli","year":"2019","journal-title":"Hamostaseologie"},{"key":"R29-20251125","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia.","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:00:18Z","timestamp":1764072018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":29,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037909","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}